BACKGROUND AND PURPOSE: Insulin-like growth factor I (IGF-I) exerts neuroprotective effects in both white and gray matter under different detrimental conditions. The purpose of this review is to collect the evidence whether IGF-I is a candidate neuroprotective drug in patients with acute ischemic stroke. RESULTS: IGF-I was found to be neuroprotective in animal models of focal brain ischemia when given >or=2 hours after the insult. Different routes of administration (eg, cerebroventricular, intravenous, and intranasal) were found to be effective. In addition to inhibition of apoptosis and reduction of the infarct volume, IGF-I also improved neurological outcome. Furthermore, there are strong indications that IGF-I can also stimulate the regeneration of neural tissue. CONCLUSIONS: Additional studies are required to reveal the neuroprotective mechanisms of IGF-I in detail and to elucidate the role of IGF-binding proteins. Preclinical studies in relevant animal models for studying stroke (ie, hypertensive, diabetic, or aged animals) should be done testing different doses and routes of IGF-I administration and different combinations of IGF-I and IGF-binding proteins.
BACKGROUND AND PURPOSE:Insulin-like growth factor I (IGF-I) exerts neuroprotective effects in both white and gray matter under different detrimental conditions. The purpose of this review is to collect the evidence whether IGF-I is a candidate neuroprotective drug in patients with acute ischemic stroke. RESULTS:IGF-I was found to be neuroprotective in animal models of focal brain ischemia when given >or=2 hours after the insult. Different routes of administration (eg, cerebroventricular, intravenous, and intranasal) were found to be effective. In addition to inhibition of apoptosis and reduction of the infarct volume, IGF-I also improved neurological outcome. Furthermore, there are strong indications that IGF-I can also stimulate the regeneration of neural tissue. CONCLUSIONS: Additional studies are required to reveal the neuroprotective mechanisms of IGF-I in detail and to elucidate the role of IGF-binding proteins. Preclinical studies in relevant animal models for studying stroke (ie, hypertensive, diabetic, or aged animals) should be done testing different doses and routes of IGF-I administration and different combinations of IGF-I and IGF-binding proteins.
Authors: Sushil Sharma; Bing Yang; Roger Strong; XiaoPei Xi; Miranda Brenneman; James C Grotta; Jaroslaw Aronowski; Sean I Savitz Journal: J Neurosci Res Date: 2010-10 Impact factor: 4.164
Authors: Hady Felfly; Jin Xue; Alexander C Zambon; Alysson Muotri; Dan Zhou; Gabriel G Haddad Journal: Am J Physiol Regul Integr Comp Physiol Date: 2011-06-15 Impact factor: 3.619
Authors: Han Yan; Matthew Mitschelen; Peter Toth; Nicole M Ashpole; Julie A Farley; Erik L Hodges; Junie P Warrington; Song Han; Kar-Ming Fung; Anna Csiszar; Zoltan Ungvari; William E Sonntag Journal: J Gerontol A Biol Sci Med Sci Date: 2014-08-06 Impact factor: 6.053
Authors: Stepani Bendel; Timo Koivisto; Olli-Pekka Ryynänen; Esko Ruokonen; Jarkko Romppanen; Vesa Kiviniemi; Ari Uusaro Journal: Crit Care Date: 2010-04-28 Impact factor: 9.097
Authors: Ross L Prentice; Sophie Paczesny; Aaron Aragaki; Lynn M Amon; Lin Chen; Sharon J Pitteri; Martin McIntosh; Pei Wang; Tina Buson Busald; Judith Hsia; Rebecca D Jackson; Jacques E Rossouw; Joann E Manson; Karen Johnson; Charles Eaton; Samir M Hanash Journal: Genome Med Date: 2010-07-28 Impact factor: 11.117
Authors: Hak Jae Kim; Su Kang Kim; Hae Jeong Park; Joo-Ho Chung; Jinman Chun; Dong Hwan Yun; Young Ock Kim Journal: Exp Ther Med Date: 2011-10-21 Impact factor: 2.447